Lagomorph Antibody Immunoassay for ALT1 Isoform Discrimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing liver disease tests, particularly those for ALT enzyme levels, are limited by the need for instruments to maintain fixed temperatures and measure enzymatic products under kinetic conditions, and they fail to distinguish between ALT1 and ALT2 isoforms, leading to false diagnoses and are not diagnostic in severe disease cases.
Innovation Solution
Development of a point-of-care immunoassay using lagomorph antibodies that specifically recognize the ALT1 isoform, allowing for accurate detection of ALT1 mass concentration even in the presence of human plasma, enabling early detection of liver disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If enzymatic assay methods are used to detect ALT levels, then liver disease can be detected, but the test cannot distinguish between ALT1 and ALT2 isoforms leading to false diagnoses
Solution Approach 1:
The invention segments the ALT detection by developing separate monoclonal antibodies (MAb 4A9 for ALT1, MAb M02A for ALT2) that specifically recognize each isoform. This allows the assay to distinguish between ALT1 (liver-specific) and ALT2 (muscle-specific) independently, eliminating false diagnoses caused by inability to differentiate isoforms.
Solution Approach 2:
The invention applies local quality by creating antibodies with specific binding properties tailored to each isoform's unique epitopes. MAb 4A9 is specifically designed to bind ALT1 epitopes while MAb M02A binds ALT2 epitopes, allowing localized detection of each isoform's contribution to total ALT activity.
2Ease of operation
If visual color reaction method is used in POC device, then instrument-free detection is achieved, but the dynamic range is limited to highly elevated ALT levels only
Solution Approach 1:
The invention changes the detection parameter from direct visual color reaction to a two-antibody immunological detection system with photometric measurement. This allows quantification across a broader dynamic range (2-300 IU/L) while maintaining POC applicability, as the method can be adapted to simple photometric devices.
3Measurement precision
If automated analytical instruments are used for ALT testing, then precise measurements under kinetic conditions are achieved, but device complexity and resource requirements increase
Solution Approach 1:
The invention extracts the essential detection function from complex automated instruments by using a simplified two-antibody immunological assay. The method separates the critical detection step (antibody-antigen binding) from the complex kinetic measurement requirements, allowing implementation in simpler POC devices while maintaining diagnostic accuracy.
4Quantity of substance
If rodent antibodies are used in the presence of human plasma, then ALT detection is possible, but plasma components interfere with antibody binding reducing assay performance
Solution Approach 1:
The invention uses human IgG1 constant regions in the monoclonal antibody designs to reduce interference from human plasma components. This human-like structure allows the antibodies to function effectively in human plasma without the same degree of interference that would affect non-human antibodies, improving assay performance in clinical samples.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immunoassay provides accurate and quantitative assessment of liver disease by correlating ALT1 mass concentration with enzyme levels, suitable for resource-poor settings and capable of detecting severe liver disease.
Implementation Method 1
contacting the blood sample from a subject with a specific binding agent that recognizes an epitope of the liver enzyme (antigen), to form an antigen-binding agent complex
Implementation Method 2
detecting the complex using a second binding agent linked to a detectable reporter
Data Source
Figure 1A~1B
Figure 2A
Figure 2A
AI summary
An immunoassay suitable for point of care to assess liver disease or function comprising contacting a blood sample from a subject with a specific binding agent that recognizes an epitope of ALT1, that is not recognized by rodent antibodies when the rodent antibodies are in the presence of human plasma, to form an antigen-binding agent complex and detecting the complex using a second or further binding agent linked to or comprising a detectable reporter; and detecting liver disease or liver function in the subject contingent upon the mass concentration of ALT1 in the sample. Kits or devices comprising lagomorph antibodies or binding agents comprising the antigen binding component thereof suitable for measuring the mass concentration of ALT1 in a blood sample from a subject to determine liver function.